A number of investment brokers have recently updated their price targets on shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

02/26/2016 – Aegerion Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 15 price target on the stock.

02/12/2016 – Aegerion Pharmaceuticals, Inc. was downgraded to “underperform” by analysts at Bank of America Merrill Lynch. They now have a USD 6 price target on the stock.

12/21/2015 – Aegerion Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Guggenheim. They now have a USD 13 price target on the stock.

11/12/2015 – Aegerion Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at JP Morgan. They now have a USD 24 price target on the stock.

11/10/2015 – Aegerion Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 16 price target on the stock.

11/10/2015 – Aegerion Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Cowen. They now have a USD 15 price target on the stock.

05/26/2015 – Aegerion Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Needham & Company.

03/24/2015 – Aegerion Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Zacks. They now have a USD 24 price target on the stock.

10/31/2014 – Aegerion Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Deutsche Bank. They now have a USD 26 price target on the stock.

05/27/2014 – Goldman Sachs began new coverage on Aegerion Pharmaceuticals, Inc. giving the company a “sell” rating. They now have a USD 27 price target on the stock.

05/07/2014 – Aegerion Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Janney Montgomery Scott. They now have a USD 90 price target on the stock.

05/07/2014 – Aegerion Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 107 price target on the stock.

05/07/2014 – Aegerion Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at Citigroup.

04/21/2014 – Aegerion Pharmaceuticals, Inc. was upgraded to “neutral” by analysts at Ned Davis Research.

11/19/2013 – Aegerion Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 110 price target on the stock.

The share price of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was up +0.86% during the last day of trading, with a day high of 2.42. 462357 shares were traded during the last session.

The stock’s 50 day moving average is 3.30 and its 200 day moving average is 7.57. The stock’s market capitalization is 67.98M. Aegerion Pharmaceuticals, Inc. has a 52-week low of 2.26 and a 52-week high of 21.21.

View other investors thoughts on Aegerion Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.